| Literature DB >> 34512548 |
Hai-Dan Wang1, Cai-Shun Zhang1, Man-Wen Li1, Qian Lin1, Qing Zhang1, De-Feng Liu2, Zheng-Ye Ma2, Jing Dong1,3.
Abstract
Background: Insulin resistance is a metabolic disorder that occurs in type 2 diabetes mellitus and obesity. Genetic factors such as β3-adrenoceptor polymorphism (Trp64Arg) may be involved in IR and insulin secretion. However, their association is controversial. Therefore, the current meta-analysis was conducted to clarify the relationship between the Trp64Arg and IR.Entities:
Keywords: Trp64Arg; insulin resistance; meta-analysis; subgroup analysis; β3-adrenergic receptor gene
Mesh:
Substances:
Year: 2021 PMID: 34512548 PMCID: PMC8426512 DOI: 10.3389/fendo.2021.708139
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Flow chart of the included studies.
Characteristics of included studies.
| Author | Country | Study type | Test status | Number (Female/Male) | Age | BMI | Health condition | TA/TT (N) | Blood sample | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|
| Pierola et al. ( | Span | Case–control | Fasting | 337/50 | 50 ± 11 | 31.9 ± 5.9 | OSAS | 71/316 | Plasma | 8 |
| Pérez-Bravo et al. ( | Chile | Case–control | Fasting | 106 | 25.10 ± 5.64 | 26.65 ± 5.34 | Normal | 29/53 | Serum | 7 |
| Pérez-Bravo et al. ( | Chile | Case–control | Fasting | 82 | 23.58 ± 5.19 | 29.11 ± 6.08 | PCOS | 43/63 | Serum | 8 |
| Erhardt et al. ( | Hungary | Case–control | 75-g OGTT | 127/168 | 12.6 ± 3.2 | 30.6 ± 4.7 | Obese | 35/35 | Serum | 8 |
| de Luis et al. ( | Span | Cross-sectional | Normal | 170/94 | 41.1 ± 13.1 | 36.5 ± 5.9 | Obese | 38/226 | Plasma | 9 |
| de Luis et al. ( | Helsinki | Case–control | Normal | 154/58 | 44.8 ± 16.7 | 35.8 ± 4.9 | Obese | 50/162 | Serum | 8 |
| Dunajska et al. ( | Poland | Case–control | Fasting | 284 | 50-60 | – | Postmenopausal | 36/243 | Serum | 7 |
| Mirrakhimov et al. ( | Ethnic Kyrgyz | Cross-sectional | Fasting | 145/68 | 50.7 ± 7.6 | – | MS | 46/80 | Plasma | 8 |
| Zawodniak-Szalapska et al. ( | Poland | Case–control | 75-g OGTT | 38/22 | 13.3 ± 2.94 | – | Obese | 14/46 | Plasma | 6 |
Data are presented as mean ± standard deviation.
TA, Trp64Arg; TT, Trp64Trp; BMI, body mass index; OSAS, obstructive sleep apnea syndrome; PCOS, polycystic ovary syndrome; MS, metabolic syndrome.
Figure 2Insulin level as an index of insulin resistance. Forest plot showing the effect size of the correlation between Trp64Arg mutation and insulin resistance. 95% confidence intervals (CIs) are expressed in bars (each group) and diamond (all studies). Summary estimates are analyzed using a random-effects model. SMD, standardized mean difference.
Figure 3Funnel plot of the publication bias.
Subgroups analyses of relationship between Trp64Arg mutation and insulin resistance.
| Groups | Participants (N) | Random-effects SMD (95% CI) | |||
|---|---|---|---|---|---|
|
| 57.6 | ||||
| Overall | 9 | 1,586 | 0.20 | 0.016 | |
| Subgroup analyses | |||||
|
| |||||
| Asian | 1 | 126 | 0.13 (−0.23, 0.5) | – | – |
| South America | 2 | 188 | 0.03 (−0.35, 0.41) | 39.6 | 0.198 |
| Europe | 6 | 1,272 | 0.26 (−0.00, 0.53) | 68.3 | 0.007 |
|
| |||||
| <18 | 2 | 130 | 0.46 (−0.84, 1.77) | 90.9 | 0.001 |
| ≥18 | 7 | 1,456 | 0.15 (0.02, 0.28) | 0 | 0.713 |
|
| |||||
| Overweight | 4 | 593 | 0.07 (−0.12, 0.27) | 0 | 0.612 |
| Obesity | 5 | 993 | 0.31 (−0.01, 0.63) | 72.9 | 0.005 |
|
| |||||
| Plasma | 4 | 837 | 0.17 (−0.00, 0.34) | 0 | 0.443 |
| serum | 5 | 749 | 0.25 (−0.10, 0.61) | 75.1 | 0.003 |
| Test status | |||||
| Normal | 2 | 476 | 0.25 (0.02, 0.48) | 0 | 0.431 |
| 75-g OGTT | 2 | 130 | 0.46 (−0.84, 1.77) | 90.9 | 0.001 |
| Fasting | 5 | 980 | 0.10 (−0.05, 0.26) | 0 | 0.732 |
|
| |||||
| Overall | 6 | 1,121 | 0.08 (−0.40, 0.55) | 90.2 | 0 |
| Subgroup analysis | |||||
|
| |||||
| South America | 2 | 188 | −0.65 (−1.53, 0.23) | 87.8 | 0.004 |
| Europe | 4 | 933 | 0.40 (0.05, 0.74) | 75.4 | 0.007 |
|
| |||||
| <18 | 1 | 70 | 1.12 (0.61, 1.62) | – | – |
| ≥18 | 5 | 1,051 | −0.01 (−0.56, 0.34) | 88.1 | 0 |
| BMI | |||||
| Overweight | 2 | 188 | −0.65 (−1.53, 0.23) | 87.8 | 0.004 |
| Obesity | 4 | 933 | 0.40 (0.05, 0.74) | 75.4 | 0.007 |
|
| |||||
| Plasma | 2 | 651 | 0.22 (0.02, 0.43) | 0 | 0.356 |
| serum | 4 | 470 | −0.01 (−0.83, 0.81) | 93.6 | 0 |
| Test status | |||||
| Normal | 2 | 0.25 (0.02, 0.48) | 0 | 0.431 | |
| 75-g OGTT | 1 | 1.12 (0.61, 1.62) | – | – | |
| Fasting | 3 | −0.37 (−1.12, 0.38) | 91.9 | 0 |
Data presented as mean ± SD.
OGTT, oral glucose tolerance test; OSAS, obstructive sleep apnea syndrome; PCOS, polycystic ovary syndrome; MS, metabolic syndrome; TA, Trp64Arg; TT, Trp64Trp.
Figure 4Forest plot of correlations between Trp64Arg mutation and insulin resistance-based onset status. 95% confidence intervals (CI) are expressed in bars (each group) and diamond (all studies). Summary estimates were analyzed using a random-effects model. Pierola et al., Pérez-Bravo et al., Dunajska et al., and Mirrakhimov et al. presented data from people with fasting test status; Erhardt et al. and Zawodniak-Szalapska et al. presented data from people with 75-g OGTT test status. de Luis et al. presented data from people with normal test status. SMD, standardized mean difference; OGTT, oral glucose tolerance test.
Figure 5Using HOMA as an index of insulin resistance. Forest plot showing the effect size of the correlation between Trp64Arg mutation and insulin resistance. 95% confidence intervals (CIs) are expressed in bars (each group) and diamond (all studies). Summary estimates are analyzed using a random-effects model. SMD, standardized mean difference.
Meta-regression of correlations between Trp64Arg and insulin resistance.
| Coefficient β | SE | 95% CI | ||
|---|---|---|---|---|
| Country | 0.231 | 0.424 | (−1.119, 1.580) | 0.624 |
| Test status | −0.066 | 0.307 | (−1.042, 0.909) | 0.842 |
| BMI | −0.702 | 0.829 | (−3.340, 1.937) | 0.459 |
| Blood sample | 0.398 | 0.490 | (−1.163, 1.959) | 0.476 |
| Age | −0.001 | 0.300 | (−0.956, 0.954) | 0.997 |
BMI, body mass index.
Figure 6Cumulative analysis.